Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Sells $103,404.84 in Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Seshu Tyagarajan sold 14,322 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $7.22, for a total transaction of $103,404.84. Following the transaction, the chief technology officer now directly owns 96,790 shares of the company’s stock, valued at approximately $698,823.80. This trade represents a 12.89 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Seshu Tyagarajan also recently made the following trade(s):

• On Friday, November 29th, Seshu Tyagarajan sold 20,392 shares of Candel Therapeutics stock. The stock was sold at an average price of $4.56, for a total value of $92,987.52.

Candel Therapeutics Price Performance

Shares of NASDAQ CADL opened at $6.66 on Friday. The stock has a market capitalization of $216.32 million, a price-to-earnings ratio of -3.85 and a beta of -1.20. The firm’s 50 day simple moving average is $6.61 and its 200-day simple moving average is $6.28. Candel Therapeutics, Inc. has a 12 month low of $1.16 and a 12 month high of $14.60.

Institutional Trading of Candel Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Point72 DIFC Ltd acquired a new position in shares of Candel Therapeutics in the second quarter worth about $31,000. FMR LLC purchased a new position in shares of Candel Therapeutics in the 3rd quarter valued at about $46,000. MetLife Investment Management LLC purchased a new position in shares of Candel Therapeutics in the 3rd quarter valued at about $87,000. Atom Investors LP acquired a new position in Candel Therapeutics in the 3rd quarter worth about $103,000. Finally, State Street Corp boosted its position in Candel Therapeutics by 4.1% during the third quarter. State Street Corp now owns 492,005 shares of the company’s stock worth $3,410,000 after purchasing an additional 19,207 shares in the last quarter. 13.93% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $19.00 target price (up previously from $11.00) on shares of Candel Therapeutics in a research note on Wednesday, December 18th.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.